Shopping Cart 0
Cart Subtotal
USD 0

Curis Inc (CRIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Curis Inc (Curis) is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating human cancers with substantial unmet medical need. It has three drug candidates in development, CUDC-907 for diffuse large B-cell lymphoma (DLBCL) and solid tumors; CA-170 for advanced solid tumors or lymphoma; and CA-4948 for advanced non-Hodgkin lymphomas. The company in collaboration with Genentech (a member of the Roche group) has developed Erivedge (vismodegib), a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor. Erivedgeis approved for the treatment of advanced basal cell carcinoma (BCC). Curis is headquartered in Lexington, Massachusetts, the US.

Curis Inc (CRIS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Curis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Curis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Curis Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Aurigene Discovery Enters into Agreement with Curis 10

Licensing Agreements 12

Curis Exercises Option for Licensing Agreement with Aurigene Discovery 12

Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 14

Curis Enters into License Agreement with Guangzhou BeBetter Medicine 15

Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 16

Equity Offering 17

Curis Plans to Raise up to USD200 Million in Public Offering of Shares 17

Curis Plans to Raise up to USD23.6 Million in Public Offering of Shares 18

Curis Raises USD37 Million in Public Offering of Shares 19

Curis Raises USD69 Million in Public Offering of Shares 21

Curis Completes Public Offering Of Shares For USD 1.2 Million 23

Curis Inc-Key Competitors 24

Curis Inc-Key Employees 25

Curis Inc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

May 03, 2018: Curis Reports First Quarter 2018 Financial Results 27

Mar 08, 2018: Curis Reports Fourth Quarter and Year-End 2017 Financial Results 29

Aug 03, 2017: Curis Reports Second Quarter 2017 Financial Results 31

May 04, 2017: Curis Reports First Quarter 2017 Financial Results 33

Mar 09, 2017: Curis Reports Fourth Quarter and Year-End 2016 Financial Results 35

Corporate Communications 38

Sep 24, 2018: Curis names James E. Dentzer as President and Chief Executive Officer 38

Apr 30, 2018: Cue Biopharma Announces Management Changes 39

Clinical Trials 40

May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 40

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

Curis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Curis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Curis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Curis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Curis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Curis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curis Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Curis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Aurigene Discovery Enters into Agreement with Curis 10

Curis Exercises Option for Licensing Agreement with Aurigene Discovery 12

Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 14

Curis Enters into License Agreement with Guangzhou BeBetter Medicine 15

Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 16

Curis Plans to Raise up to USD200 Million in Public Offering of Shares 17

Curis Plans to Raise up to USD23.6 Million in Public Offering of Shares 18

Curis Raises USD37 Million in Public Offering of Shares 19

Curis Raises USD69 Million in Public Offering of Shares 21

Curis Completes Public Offering Of Shares For USD 1.2 Million 23

Curis Inc, Key Competitors 24

Curis Inc, Key Employees 25

Curis Inc, Subsidiaries 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Curis Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Curis Inc (Curis) is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating human cancers with substantial unmet medical need. It has three drug candidates in development, CUDC-907 for diffuse large B-cell lymphoma (DLBCL) and solid tumors; CA-170 for advanced solid tumors or lymphoma; and CA-4948 for advanced non-Hodgkin lymphomas. The company in collaboration with Genentech (a member of the Roche group) has developed Erivedge (vismodegib), a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor. Erivedgeis approved for the treatment of advanced basal cell carcinoma (BCC). Curis is headquartered in Lexington, Massachusetts, the US.

Curis Inc (CRIS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Curis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Curis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Curis Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Aurigene Discovery Enters into Agreement with Curis 10

Licensing Agreements 12

Curis Exercises Option for Licensing Agreement with Aurigene Discovery 12

Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 14

Curis Enters into License Agreement with Guangzhou BeBetter Medicine 15

Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 16

Equity Offering 17

Curis Plans to Raise up to USD200 Million in Public Offering of Shares 17

Curis Plans to Raise up to USD23.6 Million in Public Offering of Shares 18

Curis Raises USD37 Million in Public Offering of Shares 19

Curis Raises USD69 Million in Public Offering of Shares 21

Curis Completes Public Offering Of Shares For USD 1.2 Million 23

Curis Inc-Key Competitors 24

Curis Inc-Key Employees 25

Curis Inc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

May 03, 2018: Curis Reports First Quarter 2018 Financial Results 27

Mar 08, 2018: Curis Reports Fourth Quarter and Year-End 2017 Financial Results 29

Aug 03, 2017: Curis Reports Second Quarter 2017 Financial Results 31

May 04, 2017: Curis Reports First Quarter 2017 Financial Results 33

Mar 09, 2017: Curis Reports Fourth Quarter and Year-End 2016 Financial Results 35

Corporate Communications 38

Sep 24, 2018: Curis names James E. Dentzer as President and Chief Executive Officer 38

Apr 30, 2018: Cue Biopharma Announces Management Changes 39

Clinical Trials 40

May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 40

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

Curis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Curis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Curis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Curis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Curis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Curis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Curis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Curis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Curis Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Curis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Aurigene Discovery Enters into Agreement with Curis 10

Curis Exercises Option for Licensing Agreement with Aurigene Discovery 12

Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 14

Curis Enters into License Agreement with Guangzhou BeBetter Medicine 15

Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 16

Curis Plans to Raise up to USD200 Million in Public Offering of Shares 17

Curis Plans to Raise up to USD23.6 Million in Public Offering of Shares 18

Curis Raises USD37 Million in Public Offering of Shares 19

Curis Raises USD69 Million in Public Offering of Shares 21

Curis Completes Public Offering Of Shares For USD 1.2 Million 23

Curis Inc, Key Competitors 24

Curis Inc, Key Employees 25

Curis Inc, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Curis Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.